Spark Therapeutics Stock Price, News & Analysis (NASDAQ:ONCE)

$45.91 1.15 (2.57 %)
(As of 12/14/2017 09:55 AM ET)
Previous Close$44.76
Today's Range$44.35 - $46.90
52-Week Range$41.06 - $91.75
Volume1.90 million shs
Average Volume481,123 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.15

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone215-220-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio15.80%
Quick Ratio15.80%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.18 million
Price / Sales84.20
Cash FlowN/A
Price / CashN/A
Book Value$10.73 per share
Price / Book4.28

Profitability

Trailing EPS($7.22)
Net Income$-123,650,000.00
Net Margins-1,090.11%
Return on Equity-60.01%
Return on Assets-53.26%

Miscellaneous

Employees213
Outstanding Shares37,010,000

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) announced its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.79) by $0.11. The biotechnology company earned $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company's revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.07) EPS. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

17 brokers have issued 12-month price targets for Spark Therapeutics' stock. Their forecasts range from $49.00 to $105.00. On average, they expect Spark Therapeutics' share price to reach $78.13 in the next year. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Update at ASH in four Hemophilia A patients raises new questions on variability of factor VIII expression levels associated with SPK-8011’s treatment." (12/11/2017)
  • 2. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
  • 3. Cowen Inc analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
  • 4. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board (Age 63)
  • Katherine A. High M.D., President, Chief Scientific Officer, Director (Age 65)
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director (Age 38)
  • Stephen W. Webster, Chief Financial Officer (Age 56)
  • John P Furey, Chief Operating Officer (Age 52)
  • Federico Mingozzi Ph.D., Chief Scientific Officer
  • Joseph W. La Barge Esq., General Counsel (Age 45)
  • Daniel R. Faga, Chief Business Officer (Age 37)
  • Lars G. Ekman M.D., Ph.D., Independent Director (Age 67)
  • Anand Mehra M.D., Independent Director (Age 41)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (5.00%), Janus Henderson Group PLC (2.04%), Orbimed Advisors LLC (1.16%), Victory Capital Management Inc. (1.07%), Jennison Associates LLC (0.84%) and Ameriprise Financial Inc. (0.57%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., AXA, Essex Investment Management Co. LLC and Tocqueville Asset Management L.P.. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Jennison Associates LLC, JPMorgan Chase & Co., Janus Henderson Group PLC, Perceptive Advisors LLC, Alyeska Investment Group L.P., Pictet Asset Management Ltd. and Russell Investments Group Ltd.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $45.91.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $1.66 billion and generates $20.18 million in revenue each year. The biotechnology company earns $-123,650,000.00 in net income (profit) each year or ($7.22) on an earnings per share basis. Spark Therapeutics employs 213 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 215-220-9300 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  492
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spark Therapeutics (NASDAQ:ONCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.762.822.752.57
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $78.13$91.50$83.33$64.50
Price Target Upside: 70.17% upside14.68% upside2.54% upside7.20% upside

Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History

Price Target History for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Goldman Sachs GroupDowngradeBuy -> Neutral$106.00 -> $58.00LowView Rating Details
12/13/2017BarclaysReiterated RatingBuy$54.00LowView Rating Details
12/13/2017Sanford C. BernsteinSet Price TargetBuy$90.00 -> $71.00MediumView Rating Details
12/12/2017WedbushUpgradeUnderperform -> Neutral$65.00 -> $50.00MediumView Rating Details
12/12/2017Chardan CapitalLower Price TargetBuy -> Buy$100.00 -> $60.00HighView Rating Details
12/12/2017BMO Capital MarketsSet Price TargetBuy$73.00HighView Rating Details
12/12/2017Leerink SwannDowngradeOutperform -> Market Perform$49.00HighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetBuy$105.00HighView Rating Details
12/7/2017Raymond James FinancialReiterated RatingBuy$75.00HighView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$100.00 -> $98.00N/AView Rating Details
10/16/2017SunTrust BanksSet Price TargetBuy$101.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy -> Buy$92.00 -> $101.00N/AView Rating Details
10/10/2017CowenReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$83.00HighView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Spark Therapeutics (NASDAQ:ONCE) Earnings History and Estimates Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.79)($1.90)$1.40 million$1.90 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Spark Therapeutics (NASDAQ:ONCE) Earnings Estimates

2017 EPS Consensus Estimate: ($6.70)
2018 EPS Consensus Estimate: ($6.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20175($1.77)($1.71)($1.73)
Q3 20175($1.89)($1.64)($1.78)
Q4 20175($1.84)($1.63)($1.74)
Q1 20184($2.04)($1.75)($1.91)
Q2 20184($1.93)($1.47)($1.62)
Q3 20184($1.91)($1.21)($1.51)
Q4 20183($1.85)($1.25)($1.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 94.94%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2017Katherine A HighInsiderSell5,000$71.32$356,600.00View SEC Filing  
11/16/2017Stephen W WebsterCFOSell10,000$70.14$701,400.00View SEC Filing  
11/13/2017Barge Joseph LaInsiderSell5,500$71.44$392,920.00View SEC Filing  
11/13/2017Jeffrey D MarrazzoCEOSell20,000$71.54$1,430,800.00View SEC Filing  
11/9/2017Barge Joseph LaInsiderSell3,309$71.31$235,964.79View SEC Filing  
10/31/2017Katherine A HighInsiderSell5,000$83.30$416,500.00View SEC Filing  
10/24/2017Daniel FagaInsiderSell7,500$80.96$607,200.00View SEC Filing  
10/20/2017Daniel FagaInsiderSell6,000$79.95$479,700.00View SEC Filing  
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.00View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.00View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.00View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.00View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.00View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.00View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.44View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.00View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.00View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.00View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.00View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spark Therapeutics (NASDAQ ONCE) News Headlines

Source:
DateHeadline
Spark Therapeutics (ONCE) "Buy" Rating Reaffirmed at BarclaysSpark Therapeutics' (ONCE) "Buy" Rating Reaffirmed at Barclays
www.americanbankingnews.com - December 13 at 6:56 PM
Spark Therapeutics Inc to Post Q2 2018 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (ONCE)Spark Therapeutics Inc to Post Q2 2018 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (ONCE)
www.americanbankingnews.com - December 13 at 12:22 PM
Spark Therapeutics (ONCE) "Outperform" Rating Reiterated at Sanford C. BernsteinSpark Therapeutics' (ONCE) "Outperform" Rating Reiterated at Sanford C. Bernstein
www.americanbankingnews.com - December 13 at 9:30 AM
UBS Loses Conviction In Spark Therapeutics, DowngradesUBS Loses Conviction In Spark Therapeutics, Downgrades
www.msn.com - December 12 at 4:55 PM
Spark Therapeutics: This Looks BadSpark Therapeutics: This Looks Bad
finance.yahoo.com - December 12 at 4:55 PM
Chardan Capital Lowers Spark Therapeutics (ONCE) Price Target to $60.00Chardan Capital Lowers Spark Therapeutics (ONCE) Price Target to $60.00
www.americanbankingnews.com - December 12 at 11:28 AM
Wedbush Upgrades Spark Therapeutics (ONCE) to NeutralWedbush Upgrades Spark Therapeutics (ONCE) to Neutral
www.americanbankingnews.com - December 12 at 11:28 AM
Spark Therapeutics Stock Plunges on Hemophilia Therapy DataSpark Therapeutics Stock Plunges on Hemophilia Therapy Data
www.zacks.com - December 12 at 10:47 AM
Spark Therapeutics (ONCE) PT Lowered to $73.00Spark Therapeutics (ONCE) PT Lowered to $73.00
www.americanbankingnews.com - December 12 at 8:52 AM
Analyst: Weakness In Spark Therapeutics Is OverdoneAnalyst: Weakness In Spark Therapeutics Is Overdone
www.msn.com - December 11 at 4:45 PM
[$$] Spark Therapeutics Selloff Looks Overdone[$$] Spark Therapeutics Selloff Looks Overdone
finance.yahoo.com - December 11 at 4:45 PM
Here's Why Spark Therapeutics, Inc. Is Getting Hammered TodayHere's Why Spark Therapeutics, Inc. Is Getting Hammered Today
finance.yahoo.com - December 11 at 4:45 PM
Biotech winners and losers: ASH Hematology ConferenceBiotech winners and losers: ASH Hematology Conference
finance.yahoo.com - December 11 at 4:45 PM
Spark Therapeutics Inc (ONCE) Tanks as Hemophilia A Drug Disappoints in Trial; J.P. Morgan Shares Two CentsSpark Therapeutics Inc (ONCE) Tanks as Hemophilia A Drug Disappoints in Trial; J.P. Morgan Shares Two Cents
finance.yahoo.com - December 11 at 4:45 PM
Spark Therapeutics' gene therapy program brings stock dow...Spark Therapeutics' gene therapy program brings stock dow...
finance.yahoo.com - December 11 at 4:45 PM
Spark Therapeutics CEO on the future of gene therapySpark Therapeutics CEO on the future of gene therapy
finance.yahoo.com - December 11 at 4:45 PM
Why Spark Therapeutics stock price dropped by 40% this morningWhy Spark Therapeutics stock price dropped by 40% this morning
finance.yahoo.com - December 11 at 4:45 PM
Spark Therapeutics Inc (ONCE) Receives Consensus Rating of "Buy" from BrokeragesSpark Therapeutics Inc (ONCE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 11 at 4:30 PM
Apple and Chesapeake Energy rise; Spark Therapeutics sinksApple and Chesapeake Energy rise; Spark Therapeutics sinks
marketbeat.com - December 11 at 4:28 PM
Spark Therapeutics (ONCE) Given a $105.00 Price Target at Cantor FitzgeraldSpark Therapeutics (ONCE) Given a $105.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 11 at 11:14 AM
Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and ExpositionSpark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - December 11 at 11:02 AM
Spark Therapeutics Trying To Close In On Key Technical BenchmarkSpark Therapeutics Trying To Close In On Key Technical Benchmark
finance.yahoo.com - December 11 at 11:02 AM
Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and ExpositionSpark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - December 11 at 11:02 AM
Excitement Builds Around Gene Therapy Cures For HemophiliaExcitement Builds Around Gene Therapy Cures For Hemophilia
finance.yahoo.com - December 9 at 4:34 PM
Spark Therapeutics (ONCE) Earns "Buy" Rating from Raymond James FinancialSpark Therapeutics (ONCE) Earns "Buy" Rating from Raymond James Financial
www.americanbankingnews.com - December 8 at 6:08 PM
Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of ...Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of ...
www.streetinsider.com - December 8 at 10:18 AM
[$$] Lighting a Spark for Gene Therapy[$$] Lighting a Spark for Gene Therapy
finance.yahoo.com - December 7 at 4:52 PM
With new lease, Spark Therapeutics stays true to West Phila. rootsWith new lease, Spark Therapeutics stays true to West Phila. roots
finance.yahoo.com - December 7 at 4:52 PM
With new large lease, Spark Therapeutics stays true to West Philly rootsWith new large lease, Spark Therapeutics stays true to West Philly roots
www.bizjournals.com - December 7 at 10:43 AM
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia BSpark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
finance.yahoo.com - December 7 at 10:43 AM
Gene-therapy approach to hemophilia finds success in study, Spark stock surgesGene-therapy approach to hemophilia finds success in study, Spark stock surges
finance.yahoo.com - December 7 at 10:43 AM
Spark Therapeutics Inc (ONCE): Financial Strength AnalysisSpark Therapeutics Inc (ONCE): Financial Strength Analysis
finance.yahoo.com - December 7 at 10:43 AM
Spark Therapeutics Trying To Close In On Key Technical MeasureSpark Therapeutics Trying To Close In On Key Technical Measure
finance.yahoo.com - December 6 at 10:35 AM
ETFs with exposure to Spark Therapeutics, Inc. : December 5, 2017ETFs with exposure to Spark Therapeutics, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 4:34 PM
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical ... - GlobeNewswire (press release)Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 12:01 PM
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and ExpositionSpark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - December 5 at 12:01 PM
Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:35 PM
Spark Therapeutics Inc (ONCE) Insider Katherine A. High Sells 5,000 SharesSpark Therapeutics Inc (ONCE) Insider Katherine A. High Sells 5,000 Shares
www.americanbankingnews.com - November 29 at 8:22 PM
Zacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Quarterly Sales of $10.94 MillionZacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Quarterly Sales of $10.94 Million
www.americanbankingnews.com - November 29 at 9:58 AM
$10.94 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter$10.94 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - November 29 at 6:50 AM
Zacks: Analysts Anticipate Spark Therapeutics Inc (ONCE) to Announce -$1.76 EPSZacks: Analysts Anticipate Spark Therapeutics Inc (ONCE) to Announce -$1.76 EPS
www.americanbankingnews.com - November 27 at 9:32 AM
Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.76 Per ShareSpark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.76 Per Share
www.americanbankingnews.com - November 27 at 9:14 AM
Spark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngineSpark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 26 at 9:00 AM
Spark Therapeutics, Inc. (ONCE) CFO Sells $701,400.00 in StockSpark Therapeutics, Inc. (ONCE) CFO Sells $701,400.00 in Stock
www.americanbankingnews.com - November 20 at 7:38 PM
$1 million price tag in spotlight as gene therapy becomes reality$1 million price tag in spotlight as gene therapy becomes reality
finance.yahoo.com - November 18 at 10:34 AM
Spark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Buy" from AnalystsSpark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 2:10 PM
BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE)BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE)
www.americanbankingnews.com - November 15 at 11:36 PM
Oversold Conditions For Spark Therapeutics (ONCE) - NasdaqOversold Conditions For Spark Therapeutics (ONCE) - Nasdaq
www.nasdaq.com - November 15 at 7:06 AM
Barge Joseph La Sells 3,309 Shares of Spark Therapeutics, Inc. (ONCE) StockBarge Joseph La Sells 3,309 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - November 13 at 7:54 PM
Barge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) StockBarge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - November 13 at 7:28 PM

SEC Filings

Spark Therapeutics (NASDAQ:ONCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spark Therapeutics (NASDAQ ONCE) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.